Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparative Effectiveness Study of MIST Therapy Versus Negative Pressure Wound Therapy

This study has been terminated.
(Unforseen enrollment challenges; business decision to terminate study)
Sponsor:
Information provided by (Responsible Party):
Celleration, Inc.
ClinicalTrials.gov Identifier:
NCT01200563
First received: September 10, 2010
Last updated: March 5, 2013
Last verified: March 2013
  Purpose

The purpose of this study is to evaluate the clinical and economic effectiveness of MIST Therapy vs NPWT vs MIST Therapy in conjunction with NPWT in the treatment of full thickness wounds presenting in the LTACH and SNF settings.


Condition Intervention Phase
Wounds
Device: MIST Therapy
Device: Vacuum Assisted Closure
Device: MIST Therapy and Negative Pressure Wound Therapy
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Comparative, Prospective, Randomized Study of MIST Therapy vs NPWT vs MIST Therapy in Conjunction With NPWT on the Rate of Healing and Its Economic Value in the Treatment of Full Thickness Wounds in a LTACH and SNF

Further study details as provided by Celleration, Inc.:

Primary Outcome Measures:
  • Rate of wound healing. [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Determined by the change in wound surface area/volume from the initial evaluation date to study end.


Secondary Outcome Measures:
  • Change wound exudation levels. [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    Determined by the change in amount of exudates recorded using a scale of none, mild, moderate, and heavy, from the initial evaluation date to study end.


Enrollment: 10
Study Start Date: August 2010
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Group 1
Subjects assigned to receive MIST Therapy will be treated 3 times per week. The duration of each MIST treatment will be dependent on the wound's area measured at baseline and at each weekly assessment.
Device: MIST Therapy
Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
Other Name: MIST
Active Comparator: Group 2
Subjects assigned to receive Negative Pressure Wound Therapy will be treated with the Vacuum Assisted Closure system. For administration of this study treatment, e.g., treatment cycle, target pressure and dressing changes, the manufacturer's recommended guidelines will be followed.
Device: Vacuum Assisted Closure
Controlled negative pressure (vacuum) delivering negative (sub-atmospheric) pressure to the wound site applied by a tubing which decompresses a foam dressing, continuously or intermittently depending on wound type.
Other Name: VAC Therapy
Active Comparator: Group 3
Subjects assigned to this group will receive MIST Therapy treatments and Negative Pressure Wound Therapy.
Device: MIST Therapy and Negative Pressure Wound Therapy
MIST Therapy will be provided 3 times per week, NPWT will be provided according to the manufacturer's recommended guidelines.
Other Names:
  • MIST
  • VAC Therapy

Detailed Description:

A comparative, prospective, randomized study.

Study objectives: Comparison between study groups of the assigned study treatment's effect on the rate of wound healing, cost per episode of care, severity of wound pain, and the occurrence of adverse events.

Subject recruitment: Consecutive, prospective subjects admitted to the study site will be screened for study enrollment and potential randomization. Prospective data will be collected on study subjects until at least 10 subjects are randomized into each of three treatment groups: MIST Therapy; NPWT; or MIST Therapy and NPWT.

Protocol and procedures: All randomized subjects will continue to receive standard of care treatment appropriate for their wound for the duration of their study treatment regardless of their assigned treatment group. Subjects will continue to receive assigned study treatment as long as their wound continues to show improvement, as determined by the investigator. Study treatment will continue until wound closure, or for up to 6 weeks without wound closure. A baseline evaluation will include a medical history assessment, VAS pain score, wound history and evaluation including: wound dimension measurements, overall wound assessment, digital photography, and appropriate sharp debridement, if necessary. Weekly wound assessments will include a wound evaluation, digital photography and VAS pain score. Prospective data will also be collected on specific wound care supplies and interventions provided. These data will be tracked as interventions occur while the wound continues to be treated with the assigned study treatment. Economic data will include type, quantity, duration, associated frequency, and professional time requirements.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subject of any race and at least 18 years old
  • Subject presents with full thickness wound of any etiology
  • Subject's wound is between 20cm2 and 250cm2
  • Subject's wound has less that 20% necrotic tissue
  • Subject is nutritionally stable and/or taking nutritional supplements and is being followed by a dietician
  • Subject or subject's legally authorized representative understands the nature of the study procedure(s) and provides written informed consent prior to study enrollment
  • Women of childbearing potential must not be pregnant or lactating, and must be using adequate and accepted contraceptive methods
  • Subject has a reasonable expectation of completing the study
  • Subject has had no prior MIST Therapy or Negative Pressure Wound Therapy to the enrolled wound

Exclusion Criteria:

  • Subject's condition requires the use of topical antibiotics at the time of study enrollment
  • Subject's wound would require ultrasound near an electronic implant or prosthesis, e.g., near or over the heart, or over the thoracic area if the patient is using a cardiac pacemaker
  • Subject is known to be suffering from a disorder or other situation that the subject or investigator feels would interfere with compliance or other study requirements
  • Subject is currently enrolled or has been enrolled in the last 30 days in another investigational device or drug trial
  • Subject has a combination of medical condition(s) that in the opinion of the investigator would make the subject an inappropriate candidate for the study, i.e., diabetes, including renal, hepatic, hematologic, neurologic, or immune disease
  • Subject's wound is not appropriate for Negative Pressure Wound Therapy or MIST Therapy
  • Subject has osteomyelitis, systemic sepsis, or an infection not related to his/her index wound (e.g., UTI, pulmonary) that has been untreated or has not been appropriately managed
  • Subject has a fistula(s) to the index wound bed
  • Subject's index wound is a head or neck wound
  • Subject's index wound presents with a malignancy in the wound bed
  • Subject's anticoagulation therapy is unstable
  • Subject is undergoing chemotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01200563

Locations
United States, Arizona
Trillium Specialty Hospital
Mesa, Arizona, United States, 85206
Sponsors and Collaborators
Celleration, Inc.
Investigators
Principal Investigator: Kenneth O Anaeme, MD Trillium Specialty Hospital
  More Information

No publications provided

Responsible Party: Celleration, Inc.
ClinicalTrials.gov Identifier: NCT01200563     History of Changes
Other Study ID Numbers: CR-86000
Study First Received: September 10, 2010
Last Updated: March 5, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Celleration, Inc.:
MIST Therapy
Negative Pressure Wound Therapy
Wound care in long-term acute care hospital
Wound care in skilled nursing facility setting

ClinicalTrials.gov processed this record on November 25, 2014